In a study published in The Lancet, researchers at The University of Texas Medical Branch (UTMB) report the development of new vaccines that, in animal testing, provided full protection against the deadly Andes hantavirus after a single dose. Alexander Bukreyev, PhD, head of the Laboratory of Viral Pathogenesis and Vaccine Development at UTMB, said that with backing from the National Institutes of Health, UTMB is working to fast-track these single-dose vaccines into human clinical trials.